dominant trait, although levels of LDL tend to increase with normal VLDL; familial combined (mixed) hyperlipoproteinemia-elevated levels of VLDL, LDL (iii) familial dysbetalipoproteinemia-increased LDL with increased TG and cholesterol levels (iv) familial hypertriglyceridemia-increased VLDL production with normal or decreased LDL (v) familial mixed hypertriglyceridemia-serum VLDL and chylomicrons are increased. (2) Secondary hyperlipidemia-results from disease states such as Cushing's syndrome, diabetes, liver disorders, renal disorders, thyroid disease, obesity, as well as alcohol consumption, estrogen administration, and other drug-associated changes in lipid metabolism.
Symptoms: Hyperlipidemia usually does not cause symptoms. Very high levels of lipids or triglycerides can cause yellowish nodules of fat in the skin beneath eyes, elbows and knees, and in tendons (xanthomas). Sometimes pain, swelling of organs such as the liver, spleen or pancreas (pancreatitis) or whitish rings around the eye's iris occur. Diagnosis: Diagnosis is typically based on medical history, physical examination and most importantly blood test done after overnight fasting. The blood test, measure the levels of lipids in the blood and consist of, a fasting blood test for total cholesterol (TC), LDL (bad cholesterol), HDL (good cholesterol), triglycerides (TG). American Cholesterol Education Program advises that lipids be checked at least once every five years, starting at age 20. However, more frequent or earlier testing is recommended if family history of hyperlipidemia; risk factor or disease that may cause hyperlipidemia; complication that may result from hyperlipidemia exist. Also, the American Academy of Pediatrics recommends lipid screening for children at risk (example, a family history of hyperlipidemia and/or diabetes). Prevalence: (i) A significant percentage of world population has an increased plasma lipid level, resulting in increased risk of coronary heart disease (ii) Ethnic groups adopting a 'western' lifestyle tend to have higher levels of plasma lipids (iii) Men >30 years and women >55 years (in the U.S.) have10 % rise in fasting triglyceride level >200 mg/dl (iv) Severe hypertriglyceridemia (>2000 mg/dl) higher in diabetic patients or patients suffering alcoholism (iv) Lipoprotein lipase deficiency prevalence is much higher in Quebec, Canada. (v) total C and LDL-C rise steadily about 20% in men aged 20 to 50 years, 30% in women aged 20 to 60 years and younger women have lower levels than men while homozygous familial hypercholesterolemia manifests itself from birth (vii) hyperlipidermia is higher among men than women (gender factor) (viii) total cholesterol and LDL-C levels are similar in whites and blacks, triglycerides are lower and HDL-C levels tend to be higher in the African-American population. Asian-Indians have the highest risk, Europeans have an intermediate risk while Chinese have the lowest risk (race factor) (ix) familial combined hyperlipidemia inheritance is autosomal dominant and likely to involve one of multiple enetic defects, familial hypertriglyceridemia is most likely inherited as an autosomal dominant defect, lipoprotein lipase deficiency and hepatic lipase deficiency are very rare autosomal recessive conditions hypercholesterolemia in the majority of the general public is attributed to high-fat diets and poorly understood susceptibility and modifier genes (genetics factor). Published data on the prevalence of lipid abnormalities in Nigeria are scanty. This could be attributed to low prevalence of hyperlipidemia in Nigeria prior to occidental lifestyle. Osuji et al, 2012 , reported that the current state of dyslipidemia in Nigeria clearly contradicts the previous perceptions. In their report, dsylipidemia was found to be highly prevalent in Nigeria with consistent low HDL-cholesterol and high LDL-c especially amongst the upper social class and people with other risk factors.
Other studies reported low HDL-c, with TC/HDL-c to be prevalent in the Northern part of the country while high prevalence of TC, TG and low HDL were observed in the Southern part of the country amongst people of upper social class.
Treatment
Dietary intervention: is the primary treatment strategy, but drug therapy may often be added later to augment treatment. The main component of a "heart-healthy" diet is a food pattern that is low in saturated fat and dietary cholesterol and provides adequate energy to support growth and maintain an appropriate weight. Specific dietary recommendations include: (i) decreased intakes of saturated fat-most effective in lowering LDL. Sources include stick margarine, partially hydrogenated oils and fats, hydrogenated peanut butters, commercial bakery products, commercial fried food (e.g., French fries) and high fat animal products (ii) decreased intakes of trans-fatty acids-trans-fatty acids are thought to increase LDL levels nearly as much as saturated fat and appear to lower HDL. (iii) decreased intakes of dietary cholesterol-lead to LDL reduction. Diabetic patients tend to be more sensitive to dietary cholesterol intake, which is only found in animal products (iv) balance the fatty acid composition of diet-polyunsaturated and monounsaturated fatty acids can lower LDL and could be good substitutes for saturated fats (v) increased fiber intakes-soluble fiber can contribute to LDL reduction and is now a formal part of hyperlipidemia dietary recommendations. Common sources of fiber include oats, psyllium, guar gum, pectin, barley, dried beans, fruits, vegetables, cereals, whole grains, and legumes are good sources of soluble fiber (vi) encourage antioxidant food sources such as carotenoids, vitamins C and E and antioxidant-rich foods such as whole grains, citrus fruits, melons, berries and leafy green vegetables rather than supplements (vii) reduce serum homocysteine levels-adequate intakes of folate and vitamins B 6 and B 12 as well as total fat restriction may keep homocysteine levels low. Food sources of these nutrients include fruits, dark green and leafy vegetables, fortified cereals, whole grains, lean meats and poultry.
Drug Therapy: Currently, there are many classes of medications that may be utilized in the pharmacologic management of hyperlipidemia. They are (1) HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors (statins). The cornerstone of the lipidlowering therapy in adults has rested with the HMG CoA reductase inhibitors or statins. The use of these drugs has resulted in important reductions in overall cardiovascular morbidity and mortality. Mechanism of action-reduction of cholesterol synthesis in liver; inhibiting the rate-limiting step in endogenous cholesterol synthesis; compensatory increase in synthesis of LDL receptors on hepatic and extra hepatic tissues; increase in hepatic uptake of circulating LDL which decreases plasma LDL cholesterol; increase in HDL, decrease in TGs and vasodilatation and decrease in atherosclerosis. Pharmacological indication: Clinically used in the treatment of all types of hyperlipidemia except those who are homozygous for familial hypercholesterolemia (lack of LDL receptors). (6) Lovaza (Omega-3-acid ethyl ester): Mechanism of action: is unclear; however, proposed mechanisms include decreasing lipogenesis in the liver, increasing plasma lipoprotein lipase activity, and increasing mitochondrial and perixosomal lipase activity. The drug may increase aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and has also been known to prolong bleeding time. Pharmacological indication: is indicated as adjunct therapy to diet in patients with triglyceride levels greater than or equal to 500 mg/dl (hypertriglyceridemia). It provides significant reduction in triglycerides, of approximately 44.9%, making it an ideal drug choice in patients with high triglycerides (7) Fish oil is another common overthe-counter (OTC) product that provides an alternative to the prescription product Lovaza (8) OTC herbal product: (i) Red yeast rice (RYR)-herbal supplements used for lipid-lowering effects. RYR is obtained by fermenting Monascus purpureus, a form of yeast, on rice, which is then dried, pulverized, and encapsulated. This process leads to the formation of 14 monacolins, which are compounds that inhibit HMG-CoA reductase. One of the mona-colins, monacolin K (lovastatin or mev-inolin) was the first synthesized HMG-CoA reductase inhibitor. RYR is commercially available in 600-mg capsules (ii) Plant sterols and stanols also assist in the reduction of LDL-C. Plant sterols reduce cholesterol absorption by competing with cholesterol for space within bile salt micelles in the intestinal lumen. The plant stanols, which are the result of the hydrogenation of sterols, are not absorbed as well as sterols. Ingestion of about 2 g per day of plant sterols or stanols, produces LDL-C reduction of 6% to 15%. Prevention: Cardiovascular disease (CVD) is the leading cause of mortality in advance countries, with hyperlipidemia a common risk factor for CVD, in adults having abnormal cholesterol values and elevated low-density lipoprotein (LDL) cholesterol levels. Prevention could be subdivided into: Primary prevention-(i) initial treatment is diet/exercise and should be given three to six months on dietary therapy prior to beginning medication and longer if lipids are improving and nearing LDL thresholds (ii) obtain cholesterol tests starting at the age of 20 (iii) eat a diet low in total fat, saturated fat, and cholesterol namely eat poultry without the skin, fish, vegetables, most fruits, whole grains, and skim milk (iv) reduce sugar intake (v) eat foods high in soluble fiber (vi) eat more cold water fish and soy products (vii) avoid cigarette smoking (viii) drink alcohol in moderation (two drinks per day for men, one drink per day for women) (ix) avoid overweight (x) exercise regularly and control blood sugar if diabetes is implicated (xi) increase physical activity (xii) consume a diet that contains adequate potassium, calcium, and magnesium to facilitate blood pressure control. Secondary prevention: Measuring lipids in adolescents that have strong family history of two or more coronary heart disease risk factors. In summary, US National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III in its guidelines has communicated the importance of early identification of risk, lifestyle modification, and pharmacologic treatment as the mainstay of therapy for hyperlipidemia and in the prevention of cardiovascular-related death.
The Promise of Nigeria Natural Products: Since the recognition of hyperlipiermia, a large number of plant species have been identified as having antihyperlipidermic properties and natural products are part of the current therapy for hyperlipidermia. Numerous natural products with antihyperlipidemic effect have been described in the literature. The objective of this chapter is to summarize the role of Nigeria natural products in the treatment and prevention of hyperlipidermia to date and to highlight specific classes of compounds that possess a requisite level of activity that would be considered worthy of further investigation as potential drug candidate.
Discussion

Antilipidemic agents from Nigeria flora
In Nigeria, traditional medicine has been the most popular means of healthcare from the olden days, before the emergence of alternative medicine in the form of synthetic agents. Traditional medicine can be said to be indigenous and a culture handed over to us by our anscestors as a means of surviving from various ailment obvious in every society. Due to high cost of synthetic drugs and side effects, natural products have become the best alternative strategy for the development of safe antilipidemic drugs. Various natural products both crude and isolated components found from plants are effective remedies for hyperlipidemia cases. Several proves are available in nature, indicating the positive effects of many natural product components that can be employed for the treatment of hyperlipidemia. 
Conclusion
The use of herbal or natural medicines for the treatment of various disorders has a long and extensive history. The reported plants have the potential to act as lipid-lowering agents with minimal side effects (advantage over currently synthetic drugs) and thus could find their way onto the world market as alternatives to prescribed drugs currently available to treat hyperlipidermia. Most of the studies were carried out with crude extract and administered orally. The principal families in which such activity has been reported are Acanthaceae, Apiaceae, Asteraceae, Azoaceae, Combretaceae, Cucurbitaceae, Euphorbiaceae, Fabaceae, Lamiaceae, Liliaceae, Malvaceae, Myrtaceae, Rubiaceae, Rutaceae and Zingiberaceae, Finally, all the plant species appear to be promising as hypolipidemic agents with activity mediated through various mechanisms.
